|
|
Article: Genzyme names new Head of Product Development for Campath and Merck gets FDA OK for widened use of emend.
- Article from:
- M2 Presswire
- Article date:
- January 13, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-13 January 2006-US Financial Network: Genzyme names new Head of Product Development for Campath and Merck gets FDA OK for widened use of emend(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:13012006
City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Genzyme Corp. (Nasdaq:GENZ) promoted Terry Murdock to lead product development of the oncology drug Campath. Murdock is the new senior vice president and product general manager for Genzyme Oncology. He joined the company through its merger with ILEX Oncology Inc. in San Antonio. ILEX developed Campath, the only monoclonal antibody approved by the Food and Drug ...
Related newspaper, magazine, and journal articles:
|
|
Article: News Search Engine, NewsKnowledge.com, Now Distributing ...
M2 Presswire;
January 12, 2005 ;
700+ words
... ... NewsKnowledge.com, Now Distributing Financial News USA News Feed(C)1994-2005 ... 01122005 City of Industry, CA - Financial News USA (OTC: FNWU), a next generation ... analyzing the actual web pages. Financial News USA recently announced that it ...
|
|